Transcat (NASDAQ:TRNS) Announces Quarterly Earnings Results

Transcat (NASDAQ:TRNS) released its earnings results on Tuesday. The scientific and technical instruments company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.19, FiscalAI reports. The company had revenue of $97.09 million during the quarter, compared to analyst estimates of $92.46 million. Transcat had a net margin of 0.99% and a return on equity of 5.56%.

Here are the key takeaways from Transcat’s conference call:

• Strong second-quarter growth: Revenue increased 18% to $97.1 million, while adjusted EBITDA rose 23% and adjusted EPS grew 46% to $0.64. Service revenue grew 23%, including 16% organic growth, marking the 70th consecutive quarter of year-over-year service growth.
• Service profitability improved substantially: Service gross margin expanded 220 basis points to 34.4%, helped by operating leverage, pricing, business-mix improvements, and operational-excellence initiatives. Management expects at least 100 basis points of year-over-year service gross-margin expansion in the second half.
• Full-year service outlook was raised: Transcat increased its fiscal 2027 service organic revenue-growth forecast from high single digits to low double digits, citing broad-based demand, market-share gains, improved sales execution, and better visibility into large customer wins.
• Acquisition and rental strategies remain key growth drivers: The Southeastern Biomedical Associates acquisition expands Transcat’s reach in biomedical calibration and hospital networks, while rentals are expected to grow at a low-double-digit rate over time. Distribution margins declined year over year because of lower-margin used-equipment sales, but management expects distribution-margin improvement in the second half.
• Financial capacity supports continued expansion: Operating free cash flow rose 46% to $10.9 million in the first half, while quarter-end debt was $116.9 million, with $33.1 million available under the revolving credit facility and leverage of 2.18 times.

Transcat Price Performance

Shares of Transcat stock traded up $1.60 during trading on Tuesday, reaching $89.52. 330,569 shares of the stock traded hands, compared to its average volume of 145,243. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.49 and a quick ratio of 2.11. Transcat has a 52-week low of $50.23 and a 52-week high of $100.00. The business has a fifty day simple moving average of $86.05 and a two-hundred day simple moving average of $81.71. The company has a market capitalization of $840.59 million, a price-to-earnings ratio of 241.95 and a beta of 0.66.

Insider Buying and Selling at Transcat

In related news, Director Craig D. Cairns bought 1,050 shares of the business’s stock in a transaction dated Thursday, August 6th. The shares were purchased at an average price of $93.97 per share, with a total value of $98,668.50. Following the transaction, the director owned 1,480 shares in the company, valued at $139,075.60. This trade represents a 244.19% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Christopher Gillette sold 504 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $94.23, for a total transaction of $47,491.92. Following the completion of the sale, the director owned 200 shares of the company’s stock, valued at $18,846. This trade represents a 71.59% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 1.80% of the company’s stock.

Analyst Upgrades and Downgrades

TRNS has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d+)” rating on shares of Transcat in a research report on Tuesday, August 25th. Northland Securities raised shares of Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 target price for the company in a report on Wednesday, October 21st. Finally, CJS Securities assumed coverage on Transcat in a research note on Tuesday, October 27th. They issued an “outperform” rating and a $115.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $105.00.

About Transcat

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.